Discontinuation symptoms and SSRIs.
Pollock
B G
BG
D001682:Biological Availability; D003866:Depressive Disorder / Q000188:drug therapy; D004244:Dizziness / Q000139:chemically induced; D005473:Fluoxetine / Q000009:adverse effects; D005500:Follow-Up Studies; D006207:Half-Life; D006801:Humans; D017374:Paroxetine / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000453:epidemiology / Q000209:etiology*
D005473:Fluoxetine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors